An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Nourianz

Chemical Nameistradefylline
Dosage FormTablet (oral; 20 mg, 40 mg)
Drug ClassReceptor antagonists
SystemMusculoskeletal
CompanyKyowa Kirin Inc.
Approval Year2019

Indication

  • Nourianz is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.
Last updated on 11/10/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nourianz (istradefylline) Prescribing Information2019Kyowa Kirin
Document TitleYearSource
Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study2019Expert Opinion on Pharmacotherapy
A long-term study of istradefylline safety and efficacy in patients with Parkinson disease2015Clinical Neuropharmacology
Clinical efficacy of istradefylline versus rTMS on parkinson's disease in a randomized clinical trial2015Neurology